Verona Pharma plc (NASDAQ:VRNA) Q2 2019 Results Earnings Conference Call August 6, 2019 8:00 AM ET Company Participants Stephanie Carrington - Investor Relations, Managing Director at ICR, Inc. Jan-Anders Karlsson - Chief Executive Officer Piers Morgan - Chief Financial Officer Conference Call Participants Lucy Codrington - Jefferies Liana Moussatos - Wedbush Securities Julian Harrison - BTIG Fang-Ke Huang - SunTrust Robinson Humphrey Neil Carnahan - Stifel Patrick Trucchio - Berenberg Capital Jens Lindqvis ...

Breathtaking science Developing respiratory drugs for better quality of life Jefferies Global Healthcare Conference June 2019 Nasdaq: VRNA AIM: VRP www.veronapharma.com Forward looking statements This presentation contains "forward-looking" statements that are based on the beliefs and assumptions and on information currently available to management of Verona Pharma plc (together with its consolidated subsidiaries, the "Company"). All statements other than statements of historical fact contained in this pres ...

RPL554 (dual PDE3/4 enzyme inhibitor): Baseline airway reversibility impacts immediate bronchodilation, in contrast to progressive symptom improvement Dave Singh1, Brian T. Maurer,2 Fernando Martinez,3 Thomas Bengtsson4 1. Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK; 2. Verona Pharma, plc, New York, USA; 3. Weill Cornell Medical College, New York, USA; 4. StatMind AB, Lund, Sweden Introduction Figure 1: Peak FEV1 0–3 h ensifentrine–placebo ...

Verona Pharma plc (NASDAQ:VRNA) Q1 2019 Results Earnings Conference Call May 7, 2019 8:00 AM ET Company Participants Stephanie Carrington - Investor Relations Jan-Anders Karlsson - Chief Executive Officer Piers Morgan - Chief Financial Officer Conference Call Participants Lucy Codrington - Jefferies Joon Lee - SunTrust Robinson Humphrey Liana Moussatos - Wedbush Securities Tom Shrader - BTIG Patrick Trucchio - Berenberg Capital Markets Operator Greetings. Welcome to Verona First Quarter 2019 Earnings Confer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________________________________________________________________ Form 20-F ______________________________________________________________________ (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 ...